Sharma Pravesh, Holland Ashley, Sheikh Taharat, Novy Blake, Oesterle Tyler, Platt Rheanna, Hammond Christopher J
Mayo Clinic Health System, 1221 Whipple St., Eau Claire, WI 54703, USA.
Johns Hopkins School of Medicine, 733 N Broadway, Baltimore, MD 21205, USA.
PEC Innov. 2022 Apr 28;1:100044. doi: 10.1016/j.pecinn.2022.100044. eCollection 2022 Dec.
Federal hemp legalization and ongoing shifts in US marijuana laws have led to increased population-wide use of cannabidiol (CBD) supplements, often without the knowledge of primary healthcare providers (PCPs). Given the potential risks related to CBD use, especially in vulnerable subgroups, improved communication is warranted. This study aimed to examine PCP attitudes, experiences, and practice behaviors related to CBD and provider-reported barriers to communication with patients about CBD use.
Fourteen PCPs were recruited and participated in semi-structured interviews. Transcripts were digitally analyzed using inductive thematic analysis.
Analyses identified that most PCPs had neutral views about CBD use by their patients. The study found that discussions about CBD use were initiated by patients. Most PCPs cited lack of time, discomfort, low-quality evidence, and low prioritization as reasons for not discussing CBD with patients.
PCPs rarely screen for or discuss CBD use with their patients and most of them had neutral views about CBD use by their patients. A number of barriers exist to open dialogue about CBD.
Our study is the first in-depth report on PCP attitudes, experiences, and practice behaviors related to CBD. The findings of our study have the potential to significantly impact future PCP practice behaviors. These results can inform healthcare system policies around screening for CBD use and PCP communication training. In doing so, these efforts may mitigate risk and optimize benefits related to the expanding CBD market.
联邦层面大麻合法化以及美国大麻法律的持续变化导致全人群对大麻二酚(CBD)补充剂的使用增加,而初级医疗保健提供者(PCP)往往对此并不知情。鉴于CBD使用存在潜在风险,尤其是在易受影响的亚组中,改善沟通很有必要。本研究旨在调查PCP对CBD的态度、经历和实践行为,以及提供者报告的在与患者沟通CBD使用方面的障碍。
招募了14名PCP并参与半结构化访谈。使用归纳主题分析法对访谈记录进行数字化分析。
分析发现,大多数PCP对患者使用CBD持中立态度。研究发现,关于CBD使用的讨论是由患者发起的。大多数PCP将时间不足、不适感、证据质量低和优先级低作为不与患者讨论CBD的原因。
PCP很少对患者使用CBD进行筛查或讨论,且大多数对患者使用CBD持中立态度。在关于CBD的开放对话方面存在一些障碍。
我们的研究是关于PCP对CBD的态度、经历和实践行为的首份深入报告。我们研究的结果有可能显著影响未来PCP的实践行为。这些结果可为围绕筛查CBD使用和PCP沟通培训的医疗系统政策提供参考。这样做,这些努力可能会降低与不断扩大CBD市场相关的风险并优化益处。